Subtitle:

New drugs based on recombinant DNA technology

Publisher:

Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN

Abstract:

Over the last 20 years, some 100 biopharmaceuticals have gained marketing authorization in Europe, USA and other world regions. All biopharmaceu- tical products currently approved within the EU are protein-based. The majority of the first generation products were either unmodified monoclonal antibodies or proteins used clinically to either replace or augment levels of native human proteins. With the recent advances in genomics, proteomics, pharmaceutical target validation, and lead compound identification new perspectives of bio- pharmaceutical products development emerged. Protein engineering has recently facilitated the rational development of a number of proteins displaying an altered pharmacokinetics, biodistribution and therapeutic properties. New strategies and challenges in biopharmaceuticals developments yielded the second generation of protein drugs.

Relation:

Biotechnologia, vol.66, 3 (2004)-.

Volume:

66

Issue:

3

Start page:

87

End page:

100

Detailed Resource Type:

Artykuł

Format:

application/pdf

Resource Identifier:

0860-7796 ; oai:rcin.org.pl:119236

Source:

Biblioteka Instytutu Chemii Bioorganicznej PAN

Language:

pol

Language of abstract:

eng

Temporal coverage:

1988-2010

Rights:

Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0

Terms of use:

-

Digitizing institution:

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

Original in:

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

Projects co-financed by:

Program Operacyjny Polska Cyfrowa, lata 2014-2020, Działanie 2.3 : Cyfrowa dostępność i użyteczność sektora publicznego; środki z Europejskiego Funduszu Rozwoju Regionalnego oraz współfinansowania krajowego z budżetu państwa

Access:

Otwarty